ESMO 2020 | PRINCEPS study: atezolizumab for resectable NSCLC

Benjamin Besse, MD, PhD, Institut Gustave Roussy, Villejuif, France, discusses results from the PRINCEPS study (NCT02994576), a Phase II clinical trial studying neoadjuvant atezolizumab for resectable non-small cell lung cancer (NSCLC). Results showed that surgery after one infusion of atezolizumab was safe and that the short delay between atezolizumab and surgery might explain the absence of major pathological response. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).